Palisade Bio Inc (PALI) Stock Price, Quote & News

Company Profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement wi...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 704 4900

Website: www.palisadebio.com

Address:

7750 El Camino Real, Suite 2A, Carlsbad, United States

StockHounding Oct. 25 at 3:52 PM

$EEIQ trading like a student who already knows the answers but lets everyone else guess first. It’s been holding that $0.45–$0.50 range like a champ. The Form 20-F filed Jan 31 2025 (Item 4 – Information on the Company) noted “continued growth of our international partnerships and diversified academic programs.” That’s a polite way of saying they’re scaling without breaking a sweat. $HUDI showing sparks again $UTSI quiet but building $GLG holding trend support $PALI attracting small-volume scouts Clean filings, calm tape, no drama — just the type of swing setup that sneaks up on lazy scanners. $EEIQ is one of those charts that whispers before it shouts. 📚✨

1 · Reply

biochirp Oct. 22 at 6:49 PM

$PALI I’m back in

0 · Reply

Bazzzigar Oct. 22 at 5:21 PM

$PALI KVUE

0 · Reply

Fast_Eddie_Felson Oct. 22 at 4:25 PM

$PALI timberrrrrrrrr

0 · Reply

Marolaca11 Oct. 22 at 3:06 PM

$PALI

0 · Reply

MTRADe_01 Oct. 22 at 4:14 AM

Watchlist winners don’t lie 📊 $BYND +73% $PALI +4.7% $LAC +2.2% Stay tuned — next list drops premarket 🔥

0 · Reply

DillowWesgreaves Oct. 21 at 3:47 PM

$PALI $GSIT up 45% since this post gambino, not looking too bueno... might start inverse mr gambino etf

2 · Reply

Moradaisla0415 Oct. 21 at 3:12 PM

$PALI can’t wait to see you at $3 🤩

1 · Reply

bullmarket4 Oct. 21 at 12:34 PM

$PALI

0 · Reply

BullJack Oct. 21 at 6:05 AM

$PALI 220% run up this month + perceptive advisors just bought 12,243,018 shares at $1.70 a pop. Not a huge investment but not a small investment either… and they paid it at the market. Really curious to see how high this can go.

1 · Reply

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD)

Oct 13, 2025, 8:45 AM EDT - 12 days ago

Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108

Oct 9, 2025, 5:00 PM EDT - 15 days ago

Palisade Bio Announces Cancellation of Special Meeting of Stockholders

Oct 2, 2025, 4:05 PM EDT - 22 days ago

Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option

Oct 1, 2025, 9:20 AM EDT - 24 days ago

Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock

Sep 26, 2025, 4:05 PM EDT - 4 weeks ago

Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

Sep 17, 2025, 9:00 AM EDT - 5 weeks ago

Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data

Sep 5, 2025, 8:45 AM EDT - 7 weeks ago

Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)

Aug 25, 2025, 9:00 AM EDT - 2 months ago

Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108

Aug 7, 2025, 9:15 AM EDT - 2 months ago

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

Jul 31, 2025, 8:45 AM EDT - 3 months ago

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China

Jul 23, 2025, 8:00 PM EDT - 3 months ago

Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million

Jul 22, 2025, 8:45 AM EDT - 3 months ago

Palisade Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 9, 2025, 8:45 AM EDT - 3 months ago

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

May 27, 2025, 8:30 AM EDT - 5 months ago

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis

May 6, 2025, 8:30 AM EDT - 6 months ago

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

May 1, 2025, 8:30 AM EDT - 6 months ago

Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

Apr 9, 2025, 8:30 AM EDT - 7 months ago

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

Mar 14, 2025, 8:30 AM EDT - 8 months ago

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

Mar 12, 2025, 8:30 AM EDT - 8 months ago

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

Mar 4, 2025, 8:30 AM EST - 8 months ago

Palisade Bio Participates in Virtual Investor “What This Means” Segment

Feb 20, 2025, 8:45 AM EST - 8 months ago

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

Feb 19, 2025, 9:00 AM EST - 8 months ago

Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 10, 2025, 8:45 AM EST - 9 months ago

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Jan 29, 2025, 8:45 AM EST - 9 months ago

Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress

Jan 3, 2025, 5:20 PM EST - 10 months ago

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 17, 2024, 8:30 AM EST - 11 months ago

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

Dec 13, 2024, 4:05 PM EST - 11 months ago

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Dec 12, 2024, 12:55 PM EST - 11 months ago

What's Going On With Palisade Bio Stock On Thursday?

Dec 12, 2024, 12:05 PM EST - 11 months ago

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Dec 3, 2024, 8:15 AM EST - 11 months ago

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

Nov 21, 2024, 8:15 AM EST - 1 year ago

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

Nov 12, 2024, 8:45 AM EST - 1 year ago

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

Oct 31, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

Aug 13, 2024, 8:05 AM EDT - 1 year ago

Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

Jul 31, 2024, 9:15 AM EDT - 1 year ago

Palisade Bio Participates in Virtual Investor “What this Means” Segment

Jul 29, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108

Jul 19, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108

Jul 11, 2024, 8:00 AM EDT - 1 year ago

Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Jun 24, 2024, 9:00 AM EDT - 1 year ago

Palisade Bio to Participate in the Virtual Investor Closing Bell Series

Jun 21, 2024, 8:15 AM EDT - 1 year ago

Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences

Jun 11, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108

Jun 10, 2024, 9:15 AM EDT - 1 year ago

Palisade Bio to Present at the Virtual Investor Pitch Conference

May 21, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

May 14, 2024, 8:05 AM EDT - 1 year ago

Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Appoints Margery Fischbein to its Board of Directors

May 7, 2024, 7:30 AM EDT - 1 year ago

Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

StockHounding Oct. 25 at 3:52 PM

1 · Reply

biochirp Oct. 22 at 6:49 PM

$PALI I’m back in

0 · Reply

Bazzzigar Oct. 22 at 5:21 PM

$PALI KVUE

0 · Reply

Fast_Eddie_Felson Oct. 22 at 4:25 PM

$PALI timberrrrrrrrr

0 · Reply

Marolaca11 Oct. 22 at 3:06 PM

$PALI

0 · Reply

MTRADe_01 Oct. 22 at 4:14 AM

Watchlist winners don’t lie 📊 $BYND +73% $PALI +4.7% $LAC +2.2% Stay tuned — next list drops premarket 🔥

0 · Reply

DillowWesgreaves Oct. 21 at 3:47 PM

$PALI $GSIT up 45% since this post gambino, not looking too bueno... might start inverse mr gambino etf

2 · Reply

Moradaisla0415 Oct. 21 at 3:12 PM

$PALI can’t wait to see you at $3 🤩

1 · Reply

bullmarket4 Oct. 21 at 12:34 PM

$PALI

0 · Reply

BullJack Oct. 21 at 6:05 AM

1 · Reply

RunnerSignals Oct. 20 at 8:17 PM

Red to green squad showing no mercy today 💪 $IVVD $PALI $BMBL $FOSL $CHA flipping the script like pros market warriors in full comeback mode!

0 · Reply

PremarketAnalysis Oct. 20 at 1:12 PM

$PALI SignalEngine: MM Infl (Neutral) (15m + 5m), Algo Vol 4%, Org Vol 96%, Res 1.87, Sup 1.71 Algo Int: Early buy reaction within declining structure https://premarketanalysis.com/#momentum=PALI

0 · Reply

TwongStocks Oct. 20 at 12:45 PM

$PALI Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD) https://palisadebio.com/palisade-bio-announces-first-patients-dosed-in-phase-1b-study-of-oral-first-in-class-pde4-inhibitor-prodrug-pali-2108-for-the-treatment-of-fibrostenotic-crohns-disease-fscd/

0 · Reply

blueteam55 Oct. 18 at 5:35 AM

$PALI okay I usually dont dable in pharma lotto tickets like this but most recent 13F literally shows 5 different very reputable (including steve cohen) funds taking 10% total ownership of this company, something is cooking, so here I am and I'm in.

0 · Reply

WallStreetBuyDip Oct. 17 at 9:18 PM

I’m especially more strict when it comes to trading Small + Mid caps. Some trade based on momentum or catalyst, I only buy when H% is low, nothing else. Next I’ll trade $PALI + $MMAT I keep a result summary to see if the strategy has been successful or not.

0 · Reply

moneybags77 Oct. 17 at 7:10 PM

$PALI I missed the news. How we looking folks?

0 · Reply

RunnerSignals Oct. 17 at 4:39 PM

$PALI also coming back to life with strong reversal vibes after early weakness. Biotech heat incoming!

0 · Reply

TwongStocks Oct. 16 at 8:59 PM

$PALI Forgot to mention, the second half of the filing. They are compliant. "On October 15, 2025, the Company received a minimum bid price compliance letter from the Staff confirming the Company has regained compliance with Listing Rule 5550(a)(2), and that the matter is now closed. There can be no assurance, however, that the Company will be able to maintain compliance with Listing Rule 5550(a)(2) in the future."

0 · Reply

TwongStocks Oct. 16 at 8:47 PM

$PALI "The Company reports that, as of October 15, 2025, it had cash and cash equivalents of approximately $133.3 million. The Company also reported that, as of October 15, 2025, there were 133,002,572 shares of its common stock outstanding and pre-funded warrants to purchase up to 73,271,424 shares of its common stock outstanding." https://www.sec.gov/ix?doc=/Archives/edgar/data/1357459/000149315225018324/form8-k.htm

0 · Reply

companyofone Oct. 16 at 1:48 PM

$PALI so wen compliant? Officially?

1 · Reply

biochirp Oct. 15 at 3:56 PM

$PALI load the boat in 1.5 area

0 · Reply

Shrekolas_Cage Oct. 15 at 2:10 PM

$PPCB Not making the same mistake I made with $PALI. Sold that for a small loss after it didnt do anything, three weeks later it has gone 4-5x of my entry. Pretty sure this will do the same. Holding strong @1.79

0 · Reply

Market Cap	16.14M
Revenue (ttm)	0.00
Net Income (ttm)	-14.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.12

Volume	2,280,600
Avg Vol	7,995,130
Day's Range	N/A - N/A
Shares Out	9.12M
Stochastic %K	50%
Beta	1.46
Analysts	Strong Sell
Price Target	$8.00